Liver transarterial embolizations in metastatic neuroendocrine tumors

L de Mestier, M Zappa, O Hentic, V Vilgrain… - Reviews in Endocrine …, 2017‏ - Springer
The management of patients with well-differentiated neuroendocrine tumors (NET) and non-
resectable liver metastases is challenging. Liver-directed transarterial embolization (TAE) …

[HTML][HTML] Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis

A Frilling, AK Clift, AJAT Braat, A Alsafi, HS Wasan… - Hpb, 2019‏ - Elsevier
Background Neuroendocrine liver metastases are clinically challenging due to their frequent
disseminated distribution. This study aims to present a British experience with an emerging …

Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity

AJAT Braat, SC Kappadath, H Ahmadzadehfar… - Cardiovascular and …, 2019‏ - Springer
Purpose Radioembolization of liver metastases of neuroendocrine neoplasms (NEN) has
shown promising results; however, the current literature is of limited quality. A large …

Comparison of Tc-99m MAA planar versus SPECT/CT imaging for lung shunt fraction evaluation prior to Y-90 radioembolization: are we overestimating lung shunt …

M Elsayed, B Cheng, M **ng, I Sethi, D Brandon… - Cardiovascular and …, 2021‏ - Springer
Purpose To compare lung shunt fraction (LSF) prior to Y-90 radioembolization calculated
using planar imaging versus SPECT/CT in patients with hepatocellular carcinoma (HCC) …

Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms

J Uhlig, J Nie, J Gibson, M Cecchini, S Stein, J Lacy… - Scientific Reports, 2024‏ - nature.com
To investigate incidence, treatment patterns and outcomes of gastroenteropancreatic
neuroendocrine neoplasms (GEP-NEN) in the United States. The 2019 National Cancer …

[HTML][HTML] Predictive factors for resistant disease with Medical/Radiologic/Liver-directed anti-tumor treatments in patients with advanced pancreatic neuroendocrine …

L Lee, I Ramos-Alvarez, RT Jensen - Cancers, 2022‏ - mdpi.com
Simple Summary Tumor resistance, both primary and acquired, is leading to increased
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …

Systematic review of lung shunt fraction quantification comparing SPECT/CT and planar scintigraphy for yttrium 90 radioembolization planning

H Gill, J Hiller - Clinical and Translational Imaging, 2021‏ - Springer
Purpose Yttrium 90-labeled intra-arterial liver therapy is an effective treatment for patients
with unresectable primary or metastatic liver malignancy. Optimal radioisotope dose …

Metastatic liver disease: indications for locoregional therapy and supporting data

S Shamimi-Noori, CF Gonsalves… - Seminars in …, 2017‏ - thieme-connect.com
Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical
resection is considered the only curative treatment, yet only a minority is eligible. Patients …

Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization

KY Fan, AT Wild, VG Halappa, R Kumar… - Contemporary Clinical …, 2016‏ - Elsevier
Abstract Objective Yttrium-90 (Y-90) radioembolization is an emerging treatment option for
unresectable neuroendocrine liver metastases (NELM). However, the data regarding this …

90Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres

N Nezami, N Kokabi, JC Camacho, DM Schuster… - Nuclear Medicine and …, 2018‏ - Elsevier
Introduction There are two different types of 90 Y Microspheres, glass and resin, in the
market for 90 Y radioembolization (90 Y-RE). This study aimed to investigate the dose of …